Literature DB >> 16927139

Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events.

Sumita Verma1, Ketan Ajudia, Michel Mendler, Allan Redeker.   

Abstract

We sought to assess prevalence, and utility of discriminant function (DF) and MELD score in predicting septic events (SE), type 1 hepatorenal syndrome (HRS), and short-term mortality in severe alcoholic hepatitis (AH). Charts of patients with AH (group 1) and cirrhosis without AH (group 2) were retrospectively reviewed. Severe AH, discriminant function (DF) >or= 32 was treated with pentoxifylline. One hundred ninety-five patients were enrolled in the study and divided into 2 groups: group 1, n=99, and group 2, n=96. Of those with AH, 82% had a DF >or= 32 at presentation. Group 1 patients had a higher prevalence of SE (38% versus 25%, P=.04), type 1 HRS (30% versus 9%, P=.0003), and short-term mortality (28% versus 7%, P=.0001). In patients with AH, a MELD score >or=20 (but not a DF >or= 32) at presentation was an independent predictor of a SE (odds ratio [OR] 2.8 [1.0-7.9], P=.04), HRS (OR 4.0, 95% confidence interval [CI] 1.0-16.6, P=0.05), and short-term mortality (OR 6.4, 95% CI 1.1-37.6, P=.03). Kaplan-Meier survival curves confirmed that that a MELD >or= 20 but not a DF >or= 32 was associated with a poorer survival (P = .005 and .5, respectively). In conclusion, patients with severe AH have higher prevalence of SE, HRS, and short-term mortality compared to those with cirrhosis without AH. A MELD score >or=20 at presentation is an independent predictor of these adverse events in patients with AH who have been treated with pentoxifylline.

Entities:  

Mesh:

Year:  2006        PMID: 16927139     DOI: 10.1007/s10620-006-9099-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

Review 1.  Pentoxifylline and alcoholic hepatitis.

Authors:  T R Morgan; C J McClain
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

2.  Studies on Kidney Function: The Rate of Filtration and Reabsorption in the Human Kidney.

Authors:  P B Rehberg
Journal:  Biochem J       Date:  1926       Impact factor: 3.857

3.  MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis.

Authors:  Wichit Srikureja; Namgyal L Kyulo; Bruce A Runyon; Ke-Qin Hu
Journal:  J Hepatol       Date:  2005-05       Impact factor: 25.083

4.  Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.

Authors:  E Akriviadis; R Botla; W Briggs; S Han; T Reynolds; O Shakil
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

5.  A prospective study of bacterial infections in patients with cirrhosis.

Authors:  W R Caly; E Strauss
Journal:  J Hepatol       Date:  1993-07       Impact factor: 25.083

6.  A randomized trial of prednisolone in patients with severe alcoholic hepatitis.

Authors:  M J Ramond; T Poynard; B Rueff; P Mathurin; C Théodore; J C Chaput; J P Benhamou
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245

7.  Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease.

Authors:  Adnan Said; John Williams; Jeremy Holden; Patrick Remington; Ronald Gangnon; Alexandru Musat; Michael R Lucey
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

8.  Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial.

Authors:  R L Carithers; H F Herlong; A M Diehl; E W Shaw; B Combes; H J Fallon; W C Maddrey
Journal:  Ann Intern Med       Date:  1989-05-01       Impact factor: 25.391

9.  Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis.

Authors:  A Theodossi; A L Eddleston; R Williams
Journal:  Gut       Date:  1982-01       Impact factor: 23.059

10.  Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.

Authors:  A Ginès; A Escorsell; P Ginès; J Saló; W Jiménez; L Inglada; M Navasa; J Clària; A Rimola; V Arroyo
Journal:  Gastroenterology       Date:  1993-07       Impact factor: 22.682

View more
  17 in total

Review 1.  Corticosteroids Versus Pentoxifylline for Severe Alcoholic Hepatitis: A Sequential Analysis of Randomized Controlled Trials.

Authors:  Basile Njei; Albert Do; Thomas R McCarty; Brett E Fortune
Journal:  J Clin Gastroenterol       Date:  2016 Nov/Dec       Impact factor: 3.062

Review 2.  Model for End-stage Liver Disease.

Authors:  Ashwani K Singal; Patrick S Kamath
Journal:  J Clin Exp Hepatol       Date:  2012-12-01

Review 3.  Alcoholic hepatitis and HCV interactions in the modulation of liver disease.

Authors:  C S Punzalan; T N Bukong; G Szabo
Journal:  J Viral Hepat       Date:  2015-03-06       Impact factor: 3.728

4.  Risk factors for mortality in patients with alcoholic hepatitis and assessment of prognostic models: A population-based study.

Authors:  Jack X Q Pang; Erin Ross; Meredith A Borman; Scott Zimmer; Gilaad G Kaplan; Steven J Heitman; Mark G Swain; Kelly Burak; Hude Quan; Robert P Myers
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

Review 5.  Diagnosis and treatment of alcoholic hepatitis.

Authors:  R Parker; C A McCune
Journal:  Frontline Gastroenterol       Date:  2013-11-01

Review 6.  Alcoholic steatohepatitis: management and prognosis.

Authors:  Jacquelyn J Maher
Journal:  Curr Gastroenterol Rep       Date:  2007-03

7.  Trends of Readmissions for Gastrointestinal Bleeding After Alcoholic Hepatitis: Analysis of the Nationwide Readmission Database.

Authors:  Hisham Laswi; Bashar Attar; Abdul-Rahman Abusalim; Katayoun Khoshbin; Hafeez Shaka
Journal:  Gastroenterology Res       Date:  2022-06-02

Review 8.  Pentoxifylline for alcoholic hepatitis.

Authors:  Kate Whitfield; Andrea Rambaldi; Jørn Wetterslev; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

Review 9.  Alcoholic hepatitis: current challenges and future directions.

Authors:  Ashwani K Singal; Patrick S Kamath; Gregory J Gores; Vijay H Shah
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-28       Impact factor: 11.382

Review 10.  Incorporating mucosal-associated invariant T cells into the pathogenesis of chronic liver disease.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.